Treasurer of the State of North Carolina Has $2.98 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Treasurer of the State of North Carolina increased its stake in shares of Natera, Inc. (NASDAQ:NTRAFree Report) by 4.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,639 shares of the medical research company’s stock after purchasing an additional 2,170 shares during the quarter. Treasurer of the State of North Carolina’s holdings in Natera were worth $2,984,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Weiss Asset Management LP acquired a new position in Natera in the 4th quarter valued at approximately $454,000. Millrace Asset Group Inc. acquired a new position in Natera in the 4th quarter valued at approximately $1,309,000. Hsbc Holdings PLC increased its position in Natera by 7.7% in the 4th quarter. Hsbc Holdings PLC now owns 27,014 shares of the medical research company’s stock valued at $1,682,000 after acquiring an additional 1,929 shares during the period. TCW Group Inc. increased its position in Natera by 16.9% in the 4th quarter. TCW Group Inc. now owns 67,237 shares of the medical research company’s stock valued at $4,212,000 after acquiring an additional 9,724 shares during the period. Finally, US Bancorp DE increased its position in Natera by 31.7% in the 4th quarter. US Bancorp DE now owns 17,372 shares of the medical research company’s stock valued at $1,088,000 after acquiring an additional 4,182 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on NTRA shares. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and upped their price target for the company from $68.00 to $85.00 in a research report on Tuesday, February 20th. BTIG Research upped their price objective on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Craig Hallum initiated coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 price objective on the stock. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a research note on Friday, April 5th. Finally, Robert W. Baird upped their price objective on shares of Natera from $99.00 to $117.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $101.19.

Get Our Latest Analysis on NTRA

Natera Price Performance

Natera stock opened at $110.79 on Thursday. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $112.05. The firm’s fifty day moving average price is $98.24 and its two-hundred day moving average price is $79.26. The company has a quick ratio of 3.98, a current ratio of 4.12 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRAGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The firm had revenue of $367.70 million for the quarter, compared to analyst estimates of $316.31 million. During the same period last year, the firm earned ($1.23) earnings per share. The business’s quarterly revenue was up 52.1% compared to the same quarter last year. Research analysts expect that Natera, Inc. will post -2.44 EPS for the current year.

Insider Buying and Selling at Natera

In other Natera news, insider Jonathan Sheena sold 447 shares of the firm’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total value of $40,328.34. Following the transaction, the insider now directly owns 347,731 shares of the company’s stock, valued at $31,372,290.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Steven Leonard Chapman sold 83,223 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $88.96, for a total value of $7,403,518.08. Following the completion of the sale, the chief executive officer now owns 232,004 shares in the company, valued at $20,639,075.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 447 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the sale, the insider now owns 347,731 shares of the company’s stock, valued at approximately $31,372,290.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 263,106 shares of company stock valued at $24,521,761. Corporate insiders own 7.60% of the company’s stock.

Natera Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Recommended Stories

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.